Compare BYAH & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYAH | NDRA |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 5.0M |
| IPO Year | 2024 | 2017 |
| Metric | BYAH | NDRA |
|---|---|---|
| Price | $0.17 | $4.56 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $30.00 |
| AVG Volume (30 Days) | ★ 249.3K | 62.9K |
| Earning Date | 02-06-2026 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,768,120.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 42.65 | N/A |
| 52 Week Low | $0.14 | $2.90 |
| 52 Week High | $41.49 | $11.96 |
| Indicator | BYAH | NDRA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 40.46 |
| Support Level | N/A | $4.19 |
| Resistance Level | N/A | $4.85 |
| Average True Range (ATR) | 0.00 | 0.27 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.00 | 41.36 |
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complimentary after-sales beauty services in its physical stores.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.